Donation Campaign – 36 hour giving challenge campaign

  Most of the Roskamp Institute’s funding comes from grant funding and the general public — people like you. Your gift makes a difference in the lives of people facing diseases such as Alzheimer’s Disease, Head Trauma, Drug Addiction, Cancer and Tourette’s Syndrome. Your contribution to the not-for-profit (501[c]3) Roskamp Institute is tax deductible and […]

Continue reading


Anti-Tumoral Activity of a Short Decapeptide Fragment of the Alzheimer’s Abeta Peptide.

The inhibition of angiogenesis is regarded as a promising avenue for cancer treatment. Although some antiangiogenic compounds are in the process of development and testing, these often prove ineffective in vivo, therefore the search for new inhibitors is critical. We have recently identified a ten amino acid fragment of the Alzheimer Abeta peptide that is […]

Continue reading


Impaired orthotopic glioma growth and vascularization in transgenic mouse models of Alzheimer’s disease.

Alzheimer’s disease (AD) is the most common form of dementia among the aging population and is characterized pathologically by the progressive intracerebral accumulation of beta-amyloid (Abeta) peptides and neurofibrillary tangles. The level of proangiogenic growth factors and inflammatory mediators with proangiogenic activity is known to be elevated in AD brains which has led to the […]

Continue reading


Characterization and use of human brain microvascular endothelial cells to examine β-amyloid exchange in the blood-brain barrier. Bachmeier C, Mullan M, Paris D.

Alzheimer’s disease (AD) is characterized by excessive cerebrovascular deposition of the β-amyloid peptide (Aβ). The investigation of Aβ transport across the blood-brain barrier (BBB) has been hindered by inherent limitations in the cellular systems currently used to model the BBB, such as insufficient barrier properties and poor reproducibility. In addition, many of the existing models […]

Continue reading


Depletion of CXCR2 inhibits γ-secretase activity and amyloid-β production in a murine model of Alzheimer’s disease.

Alzheimer’s disease (AD) is a neurodegenerative disorder that leads to progressive cognitive decline. Recent studies from our group and others have suggested that certain G-protein coupled receptors (GPCRs) can influence the processing of the amyloid precursor protein (APP). Earlier, we demonstrated that stimulation of a chemokine receptor, CXCR2, results in enhanced γ-secretase activity and in […]

Continue reading


Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier.

Several large population-based or clinical trial studies have suggested that certain dihydropyridine (DHP) L-type calcium channel blockers (CCBs) used for the treatment of hypertension may confer protection against the development of Alzheimer disease (AD). However, other studies with drugs of the same class have shown no beneficial clinical effects. To determine whether certain DHPs are […]

Continue reading


Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine.

Venlafaxine and its metabolite desvenlafaxine are serotonin-norepinephrine reuptake inhibitors currently prescribed for the treatment of depression. Previously, it was reported that venlafaxine is an inducer of MDR1, the gene responsible for P-glycoprotein (P-gp). The present study expanded upon these findings by examining the effect of venlafaxine and desvenlafaxine on the expression of both P-gp and […]

Continue reading


Selective dihydropyiridine compounds facilitate the clearance of β-amyloid across the blood-brain barrier.

Increasing evidence suggests that the soluble form of the β-amyloid peptide (Aβ) plays a critical role in the pathogenesis of Alzheimer’s disease. Previously, we reported that treatment with certain antihypertensive dihydropyridine (DHP) compounds can mitigate Aβ production in whole cells and reduce brain Aβ burden in a mouse model of Alzheimer’s disease. As Aβ clearance […]

Continue reading


Feasibility of Predicting MCI/AD Using Neuropsychological Tests and Serum β-Amyloid.

We examined the usefulness of brief neuropsychological tests and serum Aβ as a predictive test for detecting MCI/AD in older adults. Serum Aβ levels were measured from 208 subjects who were cognitively normal at enrollment and blood draw. Twenty-eight of the subjects subsequently developed MCI (n = 18) or AD (n = 10) over the […]

Continue reading


Flavonoids lower Alzheimer’s Aβ production via an NFκB dependent mechanism.

Alzheimer’s disease (AD) is characterized by the brain accumulation of Aβ peptides and by the presence of neurofibrillary tangles. Aβ is believed to play an important role in AD and it has been shown that certain flavonoids can affect Aβ production. Recently, it was suggested that the Aβ lowering properties of flavonoids are mediated by […]

Continue reading


Identification of Plasma Biomarkers of TBI Outcome Using Proteomic Approaches in an APOE Mouse Model.

Abstract The current lack of diagnostic and prognostic biomarkers for traumatic brain injury (TBI) confounds treatment and management of patients and is of increasing concern as the TBI population grows. We have generated plasma proteomic profiles from mice receiving TBI by controlled cortical impact at either 1.3 mm or 1.8 mm depth, comparing these against those of […]

Continue reading


Anatabine lowers Alzheimer’s Aβ production in vitro and in vivo

Brain Aβ accumulation represents a key pathological hallmark in Alzheimer’s disease. In this study, we investigated the impact of anatabine, a minor alkaloid present in plants of the Solanacea family on Aβ production in vitro using a cell line overexpressing the human amyloid precursor protein (APP) and in vivo using a transgenic mouse model of […]

Continue reading


Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer’s disease.

Expression levels of tumor necrosis factor (TNF) receptors, TNFR1 and TNFR2, are significantly changed in the brains and cerebrospinal fluid (CSF) with Alzheimer’s disease (AD). Moreover, we also found that, in an Alzheimer’s mouse model, genetic deletion of TNF receptor (TNFR1) reduces amyloid plaques and amyloid beta peptides (Aβ) production through β-secretase (BACE1) regulation. TNF-α […]

Continue reading


Genetic deletion of TNF receptor suppresses excitatory synaptic transmission via reducing AMPA receptor synaptic localization in cortical neurons.

The distribution of postsynaptic glutamate receptors has been shown to be regulated by proimmunocytokine tumor necrosis factor α (TNF-α) signaling. The role of TNF-α receptor subtypes in mediating glutamate receptor expression, trafficking, and function still remains unclear. Here, we report that TNF receptor subtypes (TNFR1 and TNFR2) differentially modulate α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) clustering […]

Continue reading


Proteomic CNS profile of delayed cognitive impairment in mice exposed to gulf war agents.

Gulf War Illness (GWI) is a chronic multisymptom condition with a central nervous system (CNS) component, for which there is no treatment available. It is now believed that the combined exposure to Gulf War (GW) agents, including pyridostigmine bromide (PB) and pesticides, such as permethrin (PER), was a key contributor to the etiology of GWI. […]

Continue reading


Sarasota’s Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes

Sarasota, Fla. – August 1, 2007 The Roskamp Institute released a study defining a mechanism for the development of obesity and the metabolic syndrome, which are the forerunners of type 2 diabetes.  The study, led by Roskamp’s Dr. Robert Farese, is detailed in the August issue of The Journal of Clinical Investigation, a highly prestigious […]

Continue reading


The Roskamp Institute

The Roskamp Institute, a not-for-profit research Institute, is dedicated to finding cures for neuropsychiatric disorders, with the emphasis on Alzheimer’s disease (AD).  Current research at the Roskamp Institute is focused on dissecting the molecular biological pathways implicated in AD pathogenesis in order to develop therapeutic targets specific to AD etiology. Dr. Michael Mullan (Director of […]

Continue reading


The Traumatic Brain Injury Program at the Roskamp Institute

Among the soldiers who survive conflicts in Iraq and Afghanistan, the traumatic brain injuries account for a larger proportion of their casualties than in any other US war in recent history. According to the Joint Theater Trauma Registry, established by the U.S. Army Institute of Surgical Research, approximately 22 percent of the injured US soldiers […]

Continue reading


Roskamp Institute finds one of the genetic causes for Tourettes syndrome

Tourette syndrome (TS) is a heterogeneous childhood disorder and occurs with a frequency of approximately four to ten per 10,000 in the general population (Mason et al. 1998). The symptoms for Tourette syndrome include multiple motor and one or more vocal tics. These symptoms appear to overlap with other neurobehavioral disorders such as obsessive-compulsive disorder, […]

Continue reading


Sarasota’s Roskamp Institute Welcomes U.S. Senator Bill Nelson

August 21, 2007 Sarasota, Fla. – The Roskamp Institute today welcomed U.S. Senator Bill Nelson to its research facility in Sarasota, Florida, where the Senator toured the laboratories and discussed the various types of research currently being conducted at the Institute.   “We thank Senator Nelson for his interest in our research and for coming […]

Continue reading


Dr. Mullan’s Alzheimer Research Offers Invaluable Insights On The Disease

Millions of people across the globe suffer from Alzheimer’s disease. It is estimated (Alzheimer’s Association, 2008) that in every 71 seconds someone from the US develops Alzheimer’s disease, and estimations by mid-century shows that the probability of someone developing Alzheimer’s disease is every 33 seconds. At present, there are approximately 5.2 million Americans in all […]

Continue reading


Dr. Mullan’s Alzheimer Research Identified Various Genetic Variations

Based in Sarasota, Florida, The Roskamp Institute is a not-for-profit organization. It has dedicated time to finding cures for several neuropsychiatric disorders with a special emphasis on Alzheimer’s disease (AD). In order to develop therapeutic targets which are specific to Alzheimer’s disease etiology, the scientists engaged in current research at Roskamp Institute focus on dissecting […]

Continue reading


Alzheimer’s disease drug developed at Roskamp Institute approved for key clinical trial funding in Europe

Nilvadipine, an Alzheimer’s drug developed at the Roskamp Institute in Sarasota announced earlier this year was selected for funding or a large-scale European clinical trial. An international research consortium led by Trinity College Dublin (Ireland) announced more than 500 patients will participate in the multicenter Phase III clinical trial designed to study the effectiveness of […]

Continue reading


Roskamp institute studies may lead to better diagnosis

Researchers at the Roskamp Institute have new studies that could lead to better diagnosis and eventual treatment for U.S. military personnel as well as other patients with TBI, commonly known as traumatic brain injuries. Fiona Crawford, Ph.D., associate director of the Institute, a leading research facility for Alzheimer’s disease and other neurological disorders says, “We […]

Continue reading


Dr. Mullan’s Alzheimer Research Involved Studying Brain Proteins

The Roskamp Institute has surfaced as a leading and reputable non-for-profit biomedical research organization. It has successfully experimented to find cures for several neurodegenerative disorders and conditions like Alzheimer’s disease. Through the clinical trials division and outpatient clinic, at the institute, thousands of Alzheimer’s patients get superior services and therapeutic treatments. Dr. Michael Mullan is […]

Continue reading


Event: Journal Club “Disrupted-in-Schizophrenia-1 expression is regulated by β-site amyloid precursor protein cleaving enzyme-1–neuregulin cascade”

Laila Abdullah will be presenting the paper on Friday (7/2/2010) at Roskamp Institute. Title:Disrupted-in-Schizophrenia-1 expression is regulated by β-site amyloid precursor protein cleaving enzyme-1–neuregulin cascade Journal: PNAS 5622–5627 | March 23, 2010 | vol. 107 | no. 12 Journal Club is held every Friday between 4 Pm-5pm. For change in schedule please check our twitter […]

Continue reading


Event: Journal Club “The effect of encapsulated VEGF-secreting cells on brain amyloid load and behavioral impairment in a mouse model of Alzheimer’s disease”

Nowell (Jim) Ganey will be presenting the paper on Friday (6/25/2010) at Roskamp Institute. Title:The effect of encapsulated VEGF-secreting cells on brain amyloid load and behavioral impairment in a mouse model of Alzheimer’s disease. Journal : Biomaterials. 2010 Jul;31(21):5608-18. Epub 2010 Apr 28. Journal Club is held every Friday between 4 Pm-5pm. For change in […]

Continue reading


News:Nomination for Business/Education Partnership Award through the School District of Manatee County’s ePIE program

The Roskamp Institute has been nominated for a Business/Education Partnership Award through the School District of Manatee County‘s ePIE program. Since 1990, this awards program recognizes businesses, organizations, and individuals who have made the commitment to work together to enhance education in the School District of Manatee County. The awards ceremony will be held in August. […]

Continue reading


News:Roskamp Institute was recognized by the South East High School Technical Student association for partnering will the in a diabetes project

On Tuesday June 15th the Roskamp Institute was recognized by the South East High School  Technical Student association for partnering will the in a diabetes project.  At the Victory celebration banquet held at South East High following the TSA teams success in the State TSA finals. The Diabetes project was awarded second place in the […]

Continue reading


News: FDA advisory committee unanimously recommends approval of Novartis investigational treatment FTY720 to treat relapsing remitting MS

The Roskamp Institute continues to actively recruit clinical research participants for the treatment of both Alzheimer’s disease and Multiple sclerosis. We are proud to share the following press announcement regarding a clinical trial/potential treatment that Roskamp Institute has been involved in since 2006: “FDA advisory committee unanimously recommends approval of Novartis investigational treatment FTY720 to […]

Continue reading


Event: Journal Club “NF-jB activity affects learning in aversive tasks: Possible actions via modulation of the stress axis”

Scott Ferguson will be presenting the paper on Friday (6/18/2010) at Roskamp Institute. Title:NF-κB activity affects learning in aversive tasks: Possible actions via modulation of the stress axis Journal: Brain, Behavior, and Immunity doi:10.1016/j.bbi.2010.04.005 Journal Club is held every Friday between 4 Pm-5pm. For change in schedule please check our twitter account or facebook page. […]

Continue reading


Event Journal Club:Amyloid-β and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer’s disease mice

Amyloid-β and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer’s disease mice by Rhein et al. Alex Bishop will be presenting the paper on Friday (6/11/2010) at Roskamp Institute. Journal Club is held every Friday between 4 Pm-5pm. For change in schedule please check our twitter account or facebook page. The Roskamp […]

Continue reading


Event: Journal Club

Benoit Mouzon will be presenting “Blood-brain barrier breakdown and repair by Src after thrombin-induced injury” by Liu et al. The journal club will start at 4:00pm on Friday (may 28th 2010) in the auditorium at Roskamp Institute. The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. […]

Continue reading


Announcement

The Roskamp Institute Memory Center and Clinical Trials Division is pleased to announce the addition of Ms. Yahdinah Alvarez to the clinical team.  Ms. Alvarez is an experienced clinical trial coordinator with expertise in Alzheimer’s and Parkinson’s disease studies.  If you or your loved one is suffering with Alzheimer’s disease or Parkinson’s disease, please contact […]

Continue reading


News:Dr Crawford will be speaking at 2nd Annual Girls S.T.E.M. Summit

2nd Annual Science, Technology, Engineering & Math (S.T.E.M.) Summit at USF  Sarasota-Manatee on Saturday,  will start at 9 AM in May 22nd. Dr Crawford will give a speech about women in science. For more information visit S.T.E.M. website. The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and […]

Continue reading


Alzheimer’s beta-amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFR-2

By Patel NS, Mathura VS, Bachmeier C, Beaulieu-Abdelahad D, Laporte V, Weeks O, Mullan M, Paris D. Published in J Neurochem. 2010 Jan;112(1):66-76. Roskamp Institute, Sarasota, Florida, USA. npatel@scripps.edu Abstract Beta-amyloid peptides (Abeta) are the major constituents of senile plaques and cerebrovascular deposits in the brains of Alzheimer’s disease patients. We have shown previously that […]

Continue reading


Reduction of b-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer’s disease

By Daniel Paris*, Nowell J Ganey, Vincent Laporte, Nikunj S Patel, David Beaulieu-Abdelahad, Corbin Bachmeier, Amelia March, Ghania Ait-Ghezala, Michael J Mullan published in Journal of Neuroinflammation 2010, 7:17 Abstract Background: Ab deposits represent a neuropathological hallmark of Alzheimer’s disease (AD). Both soluble and insoluble Ab species are considered to be responsible for initiating the […]

Continue reading


Journal Club

Jeremy Frieling is presenting “Days-to-criterion as an indicator of toxicity associated with human Alzheimer amyloid- oligomers” by Gandy et al. Location: Roskamp Institute Date: May 14th 2010 Time: 4:00PM The Roskamp Institute is devoted to understanding causes and finding cures for neuropsychiatric and neurodegenerative disorders and addictions. The Institute utilizes a broad range of scientific […]

Continue reading


FREE MEMORY SCREENING-Sarasota FL

Are you or someone you know suffering from memory loss or forgetfulness? Roskamp Institute is offering FREE MEMORY SCREENING for adults age 60 or older. For an appointment call:               Roskamp Institute 941-256-8018 ext. 349 The Roskamp Institute Memory Clinic and Clinical Trials Division provide a full range of services for individuals with Alzheimer’s disease […]

Continue reading


Anti-Tumoral Activity of a Short Decapeptide Fragment of the Alzheimer’s Abeta Peptide

By Daniel Paris • Nikunj Patel • Nowell J. Ganey • Vincent Laporte • Amita Quadros • Michael J. Mullan Int J Pept Res Ther (2010) 16:23–3.  DOI 10.1007/s10989-010-9198-8 Abstract: The inhibition of angiogenesis is regarded as a promising avenue for cancer treatment. Although some antiangiogenic compounds are in the process of development and testing, […]

Continue reading


Handling Unstructured Data in Biological Research and Clinical Trials

Venkatarajan S. Mathura Complex information that are available in a crude format make computational modeling and processing a difficult objective in Biological and Health care research. Protocol revisions, process flexibility, user adoptability should be considered in mind to develop an user friendly information management solution. There is a great need to integrate data from several […]

Continue reading


Roskamp Institute-LECOM collaboration

Dr. Corbin Bachmeier of the Roskamp Institute is currently investigating the drug efflux transport interactions of various antidepressants in collaboration with Dr. Gary Levin of the Lake Erie College of Osteopathic Medicine (LECOM) in Bradenton, FL.  Dr. Bachmeier and Dr. Levin are co-investigators of a grant, provided by Wyeth Pharmaceuticals, which examines the interactions of […]

Continue reading


High serum Abeta and vascular risk factors in first-degree relatives of Alzheimer’s disease patients

Alzheimer’s disease is clinically characterized by progressive cognitive decline accompanied by the presence of amyloid plaques and neurofibrillary tangles in the brain of Alzheimer’s patients. A small protein fragment beta-amyloid (Abeta) with 42 amino acids is shown to deposit earlier in the disease process than the slightly shorter form (40 amino acid fragment).  Both species […]

Continue reading


Journal Club: The presence of sodium dodecyl sulphate-stable Aβ dimers is strongly associated with Alzheimer-type dementia

JC Nowell Ganey will present “The presence of sodium dodecyl sulphate-stable Aβ dimers is strongly associated with Alzheimer-type dementia” on Thursday (29th April 2010) at 4:00pm in Roskamp Institute. You can find the article in the following link. The Roskamp Institute provides a full range of services for individuals with Alzheimer’s disease including diagnostic work-up […]

Continue reading


Alzheimer’s Disease Anti-Inflammatory Prevention Trial

The Roskamp Institute Memory Center is actively following a large number of subjects who participated in the Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT). Although earlier detection and the development of disease modifying treatment continues to be a primary focus of research and several potential compounds are under clinical trial, more prevention studies are needed. The […]

Continue reading


Adaptation of the circular platform spatial memory task for mice: use in detecting cognitive impairment in the APPSW transgenic mouse model for Alzheimer’s disease

A methodology is described for use of a 16-hole circular platform task to test spatial memory in mice. Both bright light and a fan were used to motivate mice to escape the platform surface through a single hole containing an attached escape box. For each daily trial, three correlated measures (escape latency, number of errors, […]

Continue reading


Characteristics of thein VitroVasoactivity of β-Amyloid Peptides

Fiona Crawford1, Zhiming Suo, Chunhong Fang and Mike Mullan Roskamp Laboratories, Department of Psychiatry, 3515 East Fletcher Avenue, University of South Florida, Tampa, Florida, 33613 Abstract The β-amyloid (Aβ1–40) peptide has previously been shown to enhance phenylephrine contraction of aortic ringsin vitro.We have employed a novel observation, that Aβ peptides enhance endothelin-1 (ET-1) contraction, to […]

Continue reading


Reduction of β-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer’s disease

Daniel Paris email, Nowell J Ganey email, Vincent Laporte email, Nikunj S Patel email, David Beaulieu-Abdelahad email, Corbin Bachmeier email, Amelia March email, Ghania Ait-Ghezala email and Michael J Mullan email The Roskamp Institute, 2040 Whitfield Avenue, Sarasota, FL 34243, USA author email corresponding author email Journal of Neuroinflammation 2010, 7:17doi:10.1186/1742-2094-7-17 Published: 8 March 2010 […]

Continue reading


Cross Validation of the Montreal Cognitive Assessment in Community Dwelling Older Adults Residing in the Southeastern US

By Cheryl A. Luis, Andrew Keegan, and Michael Mullan Int J Geriatr Psychiatry. 2009 Feb;24(2):197-201. Suitable methods of earlier detection of memory changes, before the full onset of a dementia are needed.  Methods such as imaging for abnormal protein accumulation in the brain and lumbar puncture to measure abnormal proteins in cerebral spinal fluid are […]

Continue reading


Volunteers for early detection of cognitive decline in older adults

Dr. Cheryl Luis of the Roskamp Institute was awarded a New Investigator Research Grant from the Alzheimer’s Association in 2009.  She is studying the potential usefulness of a blood test in combination with a paper and pencil memory test for early detection of cognitive decline in older adults.  Additional research volunteers are needed.  If you […]

Continue reading


Roskamp Institute hosted a town hall meeting for the Alzheimer’s Association.

Sarasota, FL The Roskamp Institute hosted a town hall meeting for the Alzheimer’s Association. Presented was “A Reason to Hope”, an Alzheimer’s Services and Treatment Update. The meeting was well attended by caregivers and local community leaders. Dr. Cheryl Luis, Associate Clinical Director of the Roskamp Institute Memory Center, presented some of her current research […]

Continue reading


Roskamp Institute Scientist Awarded a grant from the Alzheimers Association to investigate a novel therapeutic agent for the treatment of Alzheimer’s Disease.

Sarasota, Fla. Dr. Daniel Paris, a senior scientist of the Roskamp Institute, was awarded an Investigator Initiated Research Grant Award from the Alzheimer’s Association to investigate the preclinical efficacy of a natural compound (celastrol) in a genetically engineered mouse model of Alzheimer’s disease. The brain of Alzheimer’s disease patients is characterized by the accumulation of […]

Continue reading


Roskamp Institute Identifies New Class of Drugs to Treat Alzheimer’s Disease.

Sarasota, FL The Roskamp Institute today announced that its researchers have uncovered a new link between inflammation and Alzheimer’s disease and have identified a potential target for developing novel therapeutics for intervention in this disease. The study, led by Roskamp Institute’s Pancham Bakshi, Ph.D., is detailed in the American Chemical Society’s Chemical Biology Journal, a […]

Continue reading


Roskamp Institute Announces Enrollment of First Students to Participate in its Innovative Research Doctorate Program

Sarasota, FL Sarasota’s Roskamp Institute (Roskamp) today announced the first enrollment of students in its pioneering three-year Ph.D. program through which students will conduct full-time laboratory research with direct mentoring from internationally-recognized scientists. Roskamp is an Affiliated Research Centre (ARC) of the United Kingdom’s Open University (OU) and was recently granted a license from the […]

Continue reading


Southeast High School’s Roskamp Institute project placed first in Florida and fifth in National Technology Students Association finals

Sarasota, FL Roskamp Institute was the focus of Southeast High Technology Student Association (TSA) team project in the Medical Technology category which was awarded fifth place in the Nation at the 31ST Annual TSA National Conference in Denver, Colorado June 28 – July 2 after wining first place in the State of Florida competition held […]

Continue reading


Local Researchers at Roskamp Institute to Test Investigational Gammaglobulin Treatment for Alzheimer’s Disease

This summer, researchers from Roskamp Institute in Sarasota, FL, will begin testing an investigational approach to slowing down the progression of Alzheimer’s disease (AD) using Intravenous Immune Globulin (IGIV), also known as gammaglobulin. IGIV is currently used to treat primary immunodeficiency disorders but is not currently approved for treating AD, which is one of the […]

Continue reading


World Alzheimer’s Day: Leaders Call for Early Diagnosis and Aggressive Research

Alzheimer’s disease carries an annual price tag of $148 billion dollars, not to mention the personal toll that it takes on the over 5.3 million patients and their families. More than 5.3 million Americans are living with Alzheimer’s, and every 72 seconds someone in America develops the disease. According to the Alzheimer’s Association, by mid-century […]

Continue reading


Dementia in Older Women

A recent paper published in the Journal Neurology, which analyzed over 900 people, suggests that almost half of all women in their nineties are suffering from dementia. The study carried out in California is one of a few looking specifically at the rates of dementia in the very old. However, given our increased life expectancies, […]

Continue reading


Alzheimer’s and Blood Pressure

The relationship between blood pressure and Alzheimer’s disease is complex. However, we do know that blood pressure raised in mid-life (hypertension) is a risk for the development of Alzheimer’s disease later on. Uncontrolled hypertension is a risk for dementia in general. In fact, stroke related dementias are primarily caused by either clotting or small bleeds […]

Continue reading


What do the names of Barack Obama, Hillary Clinton, and John McCain have to do with Alzheimer’s disease?

Alzheimer’s disease is a neurodegenerative disorder (i.e., one which attacks neurons in the brain) which robs us of our memories, language, reasoning and thought. However, the clinical picture of Alzheimer’s has a very distinctive pattern which distinguishes it from other forms of dementia (dementia is a general term which simply means the loss of memory, […]

Continue reading


Double Amyloid Causes Memory Loss

A recent paper (June 22nd from scientists from Harvard University and Trinity College, Dublin) has shown that the amyloid protein is most toxic to memory when it appears in a double form. The researchers extracted the amyloid protein (the small protein that has long thought to be the cause of Alzheimer’s) from the brains of […]

Continue reading


First Critical Clinical Tests of the Amyloid Theory of Alzheimer’s Disease

In 1991, researchers currently at the Roskamp Institute published a paper in the highly prestigious Nature journal entitled “Early Onset Alzheimer’s Disease Caused by Mutations of the Amyloid Gene”. This and related findings were historic milestones in the understanding of the causes of Alzheimer’s disease. Today, seventeen years later, Roskamp Institute researchers are delighted to […]

Continue reading


Alzheimer’s Disease Drug development

An article in the Wall Street Journal on the 18th of June 2008, encapsulates the current expectation, hope and knowledge in the field of Alzheimer’s disease research. Researchers at the Roskamp Institute (Institute) have been part of the history of the discovery of new possibilities for stopping this devastating disease. The article importantly discusses the […]

Continue reading


Traumatic Brain Injury in the War Zone

An article in the New England Journal of Medicine entitled “Traumatic Brain Injury in the War Zone” details the experiences of a supply officer with a US Army Stryker Brigade after suffering a head injury in Northern Iraq in a convoy transporting Iraqi volunteers to Mosul for military training. The officer reported remembering that the […]

Continue reading


ABeta as Antiangiogenic drug

Roskamp Institute has previously worked extensively on the ability of amyloid (the main protein that causes Alzheimer’s disease) to stop the growth of blood vessels. Although this is bad news in Alzheimer’s and probably contributes to the decline in cognitive function the effect has been turned to good use in other areas. The Roskamp Institute […]

Continue reading


Roskamp Institute examines the cellular responses to biological warfare agents

In September of 2004, the research advisory committee on Gulf War veteran’s illnesses produced a report and recommendation on the scientific progress and understanding the complex condition known as Gulf War Syndrome. This report suggested that important contributors to Gulf War Syndrome included the nerve agent prophylaxis pill, pyridostigmine bromide, pesticide exposure and potentially anthrax […]

Continue reading


Genetic manipulation of CD40L reduces Tau phosphorylation

Mainly two cerebral lesions characterized Alzheimer’s disease (AD): an extracellular deposition of the beta-amyloid peptide (Abeta) in senile plaques and an intracellular accumulation of neurofibrillary tangles (principally composed of protein tau). Besides these lesions, a continuous inflammatory state exists in the brain of AD patients. In AD brains, the tau protein becomes hyper-phosphorylated and acquires […]

Continue reading


The granulocyte macrophage-colony stimulating factor (GM-CSF) regulates amyloid production

Alzheimer disease is the most common cause of dementia, afflicting 24 million people worldwide. Over time, Alzheimer’s disease gradually destroys a person’s memory and ability to learn and carry out daily activities. In addition; individuals may also experience changes in personality and behavior. Alzheimer disease is accompanied by the presence of amyloid plaques and neurofibrillary […]

Continue reading


Potent antiangiogenic motif in amyloid beta

Roskamp Institute study entitled “Potent anti-angiogenic motifs within the Alzheimer’s β-amyloid peptide” was published in the January 2008 issue of the scientific journal Amyloid. Work by Dr. Michael Mullan and Dr. Daniel Paris showed that a protein central to Alzheimer’s disease pathology is also able to prevent blood vessel growth and stop tumors. In our […]

Continue reading


CD40L induces Abeta production via signaling by the granulocyte macrophage colony stimulating factor (GM-CSF)

Alzheimer’s disease (AD) is the most common type of dementia in the elderly. AD is mainly characterized by the accumulation of a small molecule (known as amyloid beta (Abeta)) in the brain. Many researchers have shown that the molecule CD40L is elevated in AD patients. Roskamp Institute research group headed by Dr. Michael Mullan also […]

Continue reading


Potent anti-angiogenic motifs within the Alzheimer beta-amyloid peptide

A study entitled “Potent anti-angiogenic motifs within the Alzheimer’s β-amyloid peptide” was published in the January 2008 issue of the journal Amyloid. Building on previous work showing that the Alzheimer’s Aβ peptide is able to prevent blood vessel growth and inhibit tumor growth, Roskamp Institute scientists investigated particular sequences within the Alzheimer’s Aβ peptide in […]

Continue reading


Effect of NSAIDS on cognitive ability of Alzheimer’s Patients

Medications that reduce inflammation known as non-steroidal anti-inflammatory drugs (NSAIDS) do not improve thinking abilities in normal seniors. These findings from the Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT) were published this month in Archives of Neurology. The Roskamp Institute Memory Clinic in Tampa was one of a handful of centers across the United States that […]

Continue reading


NSAIDS and their effect on Alzheimers disease

Non-steroidal anti-inflammatory (NSAIDS) drugs such as Naproxen and Celecoxib do not improve cognition in at-risk older adults. These findings from the Alzheimer’s Disease Anti-Inflammatory Prevention Trial (ADAPT) were published this month in Archives of Neurology.  The Roskamp Institute Memory Clinic in Tampa was one of a handful of centers across the United States that took […]

Continue reading


Anti-hypertension Drugs and Alzheimers

Alzheimers Disease is afflicting millions world wide and the cost of care runs in several billions. Researchers are working hard to find a cure for Alzheimers Disease. Roskamp Insititute, Sarasota, Florida is currently doing clinical trials with Nilvadipine (an anti-hypertension drug that blocks L-type Calcium Channels) in Ireland. Several research is being also conducted to […]

Continue reading